Differences in the immune reactions between smokers and nonsmokers may explain why only 20% of patients with lung cancer respond to immunotherapy treatment. Understanding these differences in the evolution of lung cancer between smokers and nonsmokers could be the key to unlocking new treatments.
Alterations in hepatocyte growth factor receptor (c-Met) can be oncogenic in non-small-cell lung cancer (NSCLC) as well as other cancer types. Antibody-drug conjugates (ADCs) that target c-Met have been developed to treat c-Met-expressing tumors.
Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ex19del (D), L858R (L) and T790M (T) as the more prevalent EGFR mutations, a segment of patients further acquire C797S (C)-resistant mutation. Current therapies address some single, double or triple mutation-expressing cancers. However, multiple-mutant positive cancers where T790M and/or C797S are involved pose a treatment challenge. The development of pan mutant EGFR TKIs is thus a much-desired research goal.
Lead Discovery Center GmbH and Qli5 Therapeutics GmbH have described macrocyclic compounds acting as proteasome subunit β type-5 (PSMB5) inhibitors reported to be useful for the treatment of cancer, infections, inflammatory disorders, myasthenia gravis and transplant rejection.
RSS
